{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:14:50Z","timestamp":1759580090511},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s11912-010-0126-z","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T06:03:01Z","timestamp":1283234581000},"page":"358-365","source":"Crossref","is-referenced-by-count":7,"title":["Targeted Signal Transduction Therapies in Myeloid Malignancies"],"prefix":"10.1007","volume":"12","author":[{"given":"Emma","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Perl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,1]]},"reference":[{"key":"126_CR1","unstructured":"UNAIDS: WHO Classification of Tumors of the Haemopoietic and Lymphoid Tissues. Edited by Swerdlow CE, Harris SH. WHO; 2008."},{"key":"126_CR2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408\u20132417.","journal-title":"N Engl J Med"},{"key":"126_CR3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, et al.: Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008, 22:1200\u20131206.","journal-title":"Leukemia"},{"key":"126_CR4","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540\u20133546.","journal-title":"Blood"},{"key":"126_CR5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129\u2013141.","journal-title":"Cancer Cell"},{"key":"126_CR6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399\u2013401.","journal-title":"Science"},{"key":"126_CR7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/cncr.24928","volume":"116","author":"HM Kantarjian","year":"2010","unstructured":"Kantarjian HM, et al.: Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer 2010, 116:1419\u20131430.","journal-title":"Cancer"},{"key":"126_CR8","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Saglio G, et al.: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(24):2251\u20132259.","DOI":"10.1056\/NEJMoa0912614"},{"key":"126_CR9","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Kantarjian H, et al.: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(24):2260\u20132270.","DOI":"10.1056\/NEJMoa1002315"},{"key":"126_CR10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","volume":"6","author":"W Dameshek","year":"1951","unstructured":"Dameshek W: Some speculations on the myeloproliferative syndromes. Blood 1951, 6:372\u2013375.","journal-title":"Blood"},{"key":"126_CR11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054\u20131061.","journal-title":"Lancet"},{"key":"126_CR12","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779\u20131790.","journal-title":"N Engl J Med"},{"key":"126_CR13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387\u2013397.","journal-title":"Cancer Cell"},{"key":"126_CR14","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144\u20131148.","journal-title":"Nature"},{"key":"126_CR15","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","volume":"111","author":"EO Hexner","year":"2008","unstructured":"Hexner EO, et al.: Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008, 111:5663\u20135671.","journal-title":"Blood"},{"key":"126_CR16","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","volume":"21","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, et al.: TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations. Leukemia 2007, 21:1658\u20131668.","journal-title":"Leukemia"},{"key":"126_CR17","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, et al.: Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109\u20133117.","journal-title":"Blood"},{"key":"126_CR18","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, et al.: Long-term follow up and optimized dosing regimen of INCB018424 in patients with myelofibrosis: durable clinical, functional and symptomatic responses with improved hematological safety. In 51st American Society of Hematology. New Orleans: 2009.","DOI":"10.1182\/blood.V114.22.756.756"},{"key":"126_CR19","doi-asserted-by":"crossref","unstructured":"Pardanani A, Gotlib JR, Jamieson C, et al.: A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. In 51st American Society of Hematology. New Orleans: 2009.","DOI":"10.1182\/blood.V114.22.755.755"},{"key":"126_CR20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","volume":"115","author":"FP Santos","year":"2010","unstructured":"Santos FP, et al.: Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis. Blood 2010, 115:1131\u20131136.","journal-title":"Blood"},{"key":"126_CR21","doi-asserted-by":"crossref","unstructured":"Hexner E, Goldberg JD, Prchal JT, et al.: A multicenter, open label phase I\/II study of CEP701 (lestaurtinib) in adults with myelofibrosis; a report on phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC). In 51st American Society of Hematology. New Orleans: 2009.","DOI":"10.1182\/blood.V114.22.754.754"},{"key":"126_CR22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","volume":"33","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, et al.: The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009, 33:1199\u20131203.","journal-title":"Leuk Res"},{"key":"126_CR23","doi-asserted-by":"crossref","unstructured":"Moliterno A, Hexner E, Roboz GJ, et al.: An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients. In 51st American Society of Hematology. New Orleans: 2009.","DOI":"10.1182\/blood.V114.22.753.753"},{"key":"126_CR24","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, et al.: A Phase 2 study of INCB018424, an oral, selective JAK1\/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. In 51st American Society of Hematology. New Orleans: 2009.","DOI":"10.1182\/blood.V114.22.311.311"},{"key":"126_CR25","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Harris CN: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008."},{"key":"126_CR26","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","volume":"98","author":"AH Goldstone","year":"2001","unstructured":"Goldstone AH, et al.: Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1302\u20131311.","journal-title":"Blood"},{"key":"126_CR27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2003-05-1686","volume":"103","author":"JM Rowe","year":"2004","unstructured":"Rowe JM, et al.: A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004, 103:479\u2013485.","journal-title":"Blood"},{"key":"126_CR28","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, et al.: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058\u20131066.","journal-title":"N Engl J Med"},{"key":"126_CR29","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1200\/JCO.2005.04.5450","volume":"24","author":"FG Rucker","year":"2006","unstructured":"Rucker FG, et al.: Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006, 24:3887\u20133894.","journal-title":"J Clin Oncol"},{"key":"126_CR30","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, et al.: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909\u20131918.","journal-title":"N Engl J Med"},{"key":"126_CR31","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/sj.leu.2404653","volume":"21","author":"J Suela","year":"2007","unstructured":"Suela J, et al.: DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 2007, 21:1224\u20131231.","journal-title":"Leukemia"},{"key":"126_CR32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1073\/pnas.91.2.459","volume":"91","author":"D Small","year":"1994","unstructured":"Small D, et al.: STK-1, the human homolog of Flk-2\/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor\/stem cells. Proc Natl Acad Sci U S A 1994, 91:459\u2013463.","journal-title":"Proc Natl Acad Sci USA"},{"key":"126_CR33","doi-asserted-by":"crossref","unstructured":"Small D: FLT3 mutations: biology and treatment. Hematol Am Soc Hematol Educ Program 2006, 178\u2013184.","DOI":"10.1182\/asheducation-2006.1.178"},{"key":"126_CR34","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, et al.: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97:2434\u20132439.","journal-title":"Blood"},{"key":"126_CR35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","volume":"13","author":"J Griffith","year":"2004","unstructured":"Griffith J, et al.: The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 2004, 13:169\u2013178.","journal-title":"Mol Cell"},{"key":"126_CR36","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","volume":"17","author":"M Levis","year":"2003","unstructured":"Levis M, Small D: FLT3: It does matter in leukemia. Leukemia 2003, 17:1738\u20131752.","journal-title":"Leukemia"},{"key":"126_CR37","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/sj.onc.1205332","volume":"21","author":"H Kiyoi","year":"2002","unstructured":"Kiyoi H, et al.: Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 2002, 21:2555\u20132563.","journal-title":"Oncogene"},{"key":"126_CR38","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.2001.02850.x","volume":"113","author":"FM Abu-Duhier","year":"2001","unstructured":"Abu-Duhier FM, et al.: Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001, 113:983\u2013988.","journal-title":"Br J Haematol"},{"key":"126_CR39","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752\u20131759.","journal-title":"Blood"},{"key":"126_CR40","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1080\/10428190801895352","volume":"49","author":"K Pratz","year":"2008","unstructured":"Pratz K, Levis M: Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leuk Lymphoma 2008, 49:852\u2013863.","journal-title":"Leuk Lymphoma"},{"key":"126_CR41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","volume":"105","author":"RM Stone","year":"2005","unstructured":"Stone RM, et al.: Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105:54\u201360.","journal-title":"Blood"},{"key":"126_CR42","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","volume":"103","author":"BD Smith","year":"2004","unstructured":"Smith BD, et al.: Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103:3669\u20133676.","journal-title":"Blood"},{"key":"126_CR43","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2002-10-3023","volume":"102","author":"FJ Giles","year":"2003","unstructured":"Giles FJ, et al.: SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003, 102:795\u2013801.","journal-title":"Blood"},{"key":"126_CR44","first-page":"5465","volume":"9","author":"AM O\u2019Farrell","year":"2003","unstructured":"O\u2019Farrell AM, et al.: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003, 9:5465\u20135476.","journal-title":"Clin Cancer Res"},{"key":"126_CR45","doi-asserted-by":"crossref","unstructured":"\u2022 Ravandi F, et al.: Phase I\/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010, 28(11):1856\u20131862.","DOI":"10.1200\/JCO.2009.25.4888"},{"key":"126_CR46","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1182\/blood-2008-09-177030","volume":"113","author":"KW Pratz","year":"2009","unstructured":"Pratz KW, et al.: A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009, 113:3938\u20133946.","journal-title":"Blood"},{"key":"126_CR47","doi-asserted-by":"crossref","unstructured":"Cortes JFJ, Ghirdaladze D, et al.: AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study. In 51st Meeting of the American Society of Hematology. New Orleans: 2009.","DOI":"10.1182\/blood.V114.22.636.636"},{"key":"126_CR48","doi-asserted-by":"crossref","unstructured":"Levis M, Wang RF, et al.: Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse. In 51st Meeting of the American Society of Hematology. New Orleans: 2009.","DOI":"10.1182\/blood.V114.22.788.788"},{"key":"126_CR49","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","volume":"114","author":"PP Zarrinkar","year":"2009","unstructured":"Zarrinkar PP, et al.: AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009, 114:2984\u20132992.","journal-title":"Blood"},{"key":"126_CR50","doi-asserted-by":"crossref","unstructured":"Stone RM, et al.: A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: Overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. In 51st Meeting of the American Society of Hematology. New Orleans: 2009.","DOI":"10.1182\/blood.V114.22.634.634"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-010-0126-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-010-0126-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-010-0126-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T02:10:03Z","timestamp":1591841403000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-010-0126-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["126"],"URL":"https:\/\/doi.org\/10.1007\/s11912-010-0126-z","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}